Brokers Offer Predictions for NovoCure Limited’s Q4 2025 Earnings (NASDAQ:NVCR)

NovoCure Limited (NASDAQ:NVCR) – Investment analysts at Wedbush decreased their Q4 2025 earnings per share estimates for NovoCure in a report issued on Wednesday, March 27th. Wedbush analyst D. Nierengarten now forecasts that the medical equipment provider will earn ($0.36) per share for the quarter, down from their previous estimate of ($0.35). Wedbush currently has a “Neutral” rating and a $21.00 target price on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.73) per share. Wedbush also issued estimates for NovoCure’s FY2026 earnings at ($1.45) EPS and FY2027 earnings at ($1.38) EPS.

NVCR has been the topic of several other research reports. HC Wainwright increased their target price on NovoCure from $22.00 to $24.00 and gave the stock a “neutral” rating in a report on Wednesday. JPMorgan Chase & Co. raised their price target on NovoCure from $15.00 to $17.00 and gave the company a “neutral” rating in a report on Tuesday, March 19th. Finally, Evercore ISI raised their price target on NovoCure from $14.00 to $15.00 and gave the company an “in-line” rating in a report on Friday, February 23rd. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.13.

NovoCure Trading Up 6.8 %

Shares of NVCR stock opened at $15.63 on Friday. The stock’s fifty day moving average is $14.95 and its 200-day moving average is $14.46. The company has a debt-to-equity ratio of 1.57, a quick ratio of 5.56 and a current ratio of 5.78. NovoCure has a 52 week low of $10.87 and a 52 week high of $83.60.

NovoCure (NASDAQ:NVCR) last announced its earnings results on Thursday, February 22nd. The medical equipment provider reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.08. The company had revenue of $133.80 million for the quarter, compared to analysts’ expectations of $133.80 million. NovoCure had a negative return on equity of 51.63% and a negative net margin of 40.65%. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.36) earnings per share.

Insiders Place Their Bets

In other NovoCure news, EVP Frank X. Leonard sold 1,679 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $16.03, for a total transaction of $26,914.37. Following the transaction, the executive vice president now owns 160,938 shares in the company, valued at $2,579,836.14. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, EVP Frank X. Leonard sold 1,679 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $16.03, for a total transaction of $26,914.37. Following the sale, the executive vice president now owns 160,938 shares of the company’s stock, valued at $2,579,836.14. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO Wilhelmus Cm Groenhuysen sold 2,107 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $16.03, for a total value of $33,775.21. Following the sale, the chief operating officer now directly owns 252,452 shares in the company, valued at approximately $4,046,805.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,921 shares of company stock worth $127,161. Insiders own 5.67% of the company’s stock.

Institutional Investors Weigh In On NovoCure

Hedge funds have recently modified their holdings of the business. UniSuper Management Pty Ltd acquired a new stake in shares of NovoCure during the second quarter worth about $29,000. Captrust Financial Advisors raised its position in NovoCure by 47.0% in the 2nd quarter. Captrust Financial Advisors now owns 1,292 shares of the medical equipment provider’s stock valued at $90,000 after buying an additional 413 shares during the last quarter. Lazard Asset Management LLC raised its position in NovoCure by 166.3% in the 1st quarter. Lazard Asset Management LLC now owns 1,350 shares of the medical equipment provider’s stock valued at $111,000 after buying an additional 843 shares during the last quarter. UMB Bank n.a. acquired a new stake in NovoCure in the 3rd quarter valued at approximately $26,000. Finally, EP Wealth Advisors LLC acquired a new stake in NovoCure in the 1st quarter valued at approximately $211,000. Institutional investors and hedge funds own 84.61% of the company’s stock.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.